The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients

Japanese Journal of Nephrology

Volumn 44, Issue 5, 2002, Pages 464-470

  Kasai, Kenji ^a   Abe, Ryouetsu ^b   Wakabayashi, Masanori ^c   Nakamura, Kazuyoshi ^d   Sawatani, Satoshi ^e   Wakabayashi, Tsunemichi ^c  

^a Fuji City General Hospital   (Japan)

^b Gotenba Daiichi Clinic   (Japan)

^c Department of Vascular Surgery   (Japan)

^d Fuji Daiichi Clinic   (Japan)

^e Izu Nagaoka Daiichi Clinic   (Japan)

Author keywords

Hemodialysis; Hypercalcemla; Maxacalcitol; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; ALKALINE PHOSPHATASE; CALCIUM PHOSPHATE; PARATHYROID HORMONE; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM;

ADMINISTRATION, ORAL; AGED; CALCITRIOL; CALCIUM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0036349945     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Brown AJ. Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses both parathyroid hormone synthesis and secretion. J Clin Invest 1989 ; 84 : 728-32
2. Sherrard DJ, Hercz G, Pei Y, Meloney NA, Greenwood C, Menuel A, Saiphoo C, Fenton SS, Segre G. The spectrum of bone disease in end-stage renal failure An evolving disorder. Kidney Int 1993 ; 43 : 436-42.
3. Moniere-Faugere MC, Malluche HH. Trends in renal osteodystrophy : a survey from 1983 to 1995 in a total of 2,248 patients. Nephrol Dial Transplant 1996; 11 (Suppl 3) : 111-20.
4. Tokuyama K, Iseki K, Yoshi S, Yoshihara K, Nishime K, Uehara H, Tozawa M, Wake M, Arakaki M, Fukiyama K. An epidemiologic analysis of parathyroidectomy in chronic dialysis patients. Jpn J Nephrol 1996 ; 38 : 309-13.
5. Gogusev J, Duchambon P, Hory B, Giovannini M. Goureau Y. Sarfati E, Drueke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997 ; 51 : 328-36.
6. 3 receptor density is associated with more severe form of parathyroid hyperplasia in chronic uremic patients J Clin Invest 1993 ; 92 : 1436-43.
7. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semi Surg Oncol 1997 ; 13 : 78-86.
8. Tominaga Y. Surgical management of secondary hyperparathyroidism in uremia. Am J Med Sci 1999 ; 317 : 390-7.
9. Akizawa T, Kinugasa E, Akiba T, Tsukamoto Y, Kurokawa K. Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int 1997 ; 52 : S72-4.
10. Kurokawa K, Akizawa M, Suzuki M, Akiba T, Ogata E, Slatopolsky E. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients : results of a preliminary study. Nephrol Dial Transplant 1996 ; 11 (Suppl 3) : 121-4.
11. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients : Recommendations for a change in management. Am J Kidney Dis 2000 ; 35 : 1226-37.
12. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000 ; 35 : 458-64.